Stockscreener 앱 받기
78.32
2.42%
-1.94
시간 외 거래:
78.70
0.38
+0.49%
전일 마감가:
$80.26
열려 있는:
$79.9
하루 거래량:
10.79M
Relative Volume:
2.36
시가총액:
$29.55B
수익:
$4.82B
순이익/손실:
$930.40M
주가수익비율:
33.50
EPS:
2.3381
순현금흐름:
$1.43B
1주 성능:
-10.71%
1개월 성능:
-12.52%
6개월 성능:
+23.51%
1년 성능:
+10.78%
1일 변동 폭
$77.11
$80.49
1주일 범위
$77.11
$87.08
52주 변동 폭
$54.11
$92.59
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
78.32 | 29.55B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-07 | 개시 | Barclays | Overweight |
| 2026-06-23 | 개시 | Deutsche Bank | Buy |
| 2026-05-12 | 개시 | The Benchmark Company | Buy |
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM? - Yahoo Finance
DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors - GuruFocus
Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on Octo - GuruFocus
S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers - ChartMill
Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.
DexCom Inc. Company & People | DXCM.USD - Barron's
DXCM.USD | DexCom Inc. Stock Overview (Switzerland: SWX) - Barron's
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Yahoo! Finance Canada
Form 4 DexCom Inc: Michael Jon Brown (EVP Chief Legal Compliance Off) For: 15 October By Investing.com - Investing.com South Africa
Dexcom EVP Michael Brown sells $145,316 in company stock - Investing.com
Dexcom class action lawsuits claim ShinyHunters stole health data - Top Class Actions
DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives - Seeking Alpha
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom faces a class action over an alleged data breach that ShinyHunters claimed responsibility for. - Claim Depot
Vaso Stock Surges 149% in a Year: What's Behind the Rally? - TradingView
Vaso Stock Surges 149% in a Year: What's Behind the Rally? - Zacks Investment Research
A Look at DexCom Inc (DXCM) After 5.1% Gain -- GF Value $103.59 vs Price $87.71 - GuruFocus
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom gains as NEJM publication boosts Medicare coverage hopes - TradingView
Landmark Dexcom CONNECT Study Published in The New England Journ - GuruFocus
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin - Dexcom
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Yahoo Finance
DexCom (NASDAQ:DXCM): Affordable Growth at a Reasonable Valuation - ChartMill
Here's What to Expect From DexCom’s Next Earnings Report - inkl
Here's What to Expect From DexCom’s Next Earnings Report - Yahoo Finance
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
BTIG Adjusts Price Target on DexCom to $96 From $90 - marketscreener.com
DexCom, Inc. (0A4M.L) stock price, news, quote and history - Yahoo Finance UK
DexCom, Inc. (DXCM) options chain – Yahoo Finance - Yahoo Finance Singapore
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Evercore ISI Adjusts Price Target on DexCom to $110 From $90 - marketscreener.com
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time - www.marketscreener.com
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time - Yahoo Finance
DexCom Inc (DXCM) Stock Down 4.0% -- Now Undervalued? GF Score: 95/100 - GuruFocus
DexCom Falls as Investors Appear to Take Profits Ahead of Earnings - Quiver Quantitative
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading - Business Wire
Dexcom Launches Largest Dexcom U Program Season Yet, Supporting College Athletes with Diabetes (DXCM) - GuruFocus
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
DexCom stock gains 1.22 percent ahead of October earnings - AD HOC NEWS
Continuous Glucose Monitoring Market Size, Share [2026-2034] - Fortune Business Insights
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
덱스컴 주식 (DXCM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MICHAEL BROWN | Officer |
Oct 15 '26 |
Proposed Sale |
85.48 |
1,700 |
145,316 |
0 |
| Stern Sadie | EVP Chief People & Culture Off |
Sep 28 '26 |
Sale |
86.15 |
2,565 |
220,975 |
123,478 |
| SADIE STERN | Officer |
Sep 28 '26 |
Proposed Sale |
86.15 |
2,565 |
220,975 |
0 |
| Brown Michael Jon | EVP Chief Legal Compliance Off |
Sep 15 '26 |
Sale |
84.04 |
1,700 |
142,868 |
99,885 |
| AUGUSTINOS NICHOLAS | Director |
Sep 15 '26 |
Sale |
84.04 |
6,539 |
549,538 |
29,293 |
| AUGUSTINOS NICHOLAS | Director |
Sep 15 '26 |
Proposed Sale |
84.04 |
6,539 |
549,538 |
0 |
| MICHAEL BROWN | Officer |
Sep 15 '26 |
Proposed Sale |
84.04 |
1,700 |
142,868 |
0 |
| AUGUSTINOS NICHOLAS | Director |
Sep 14 '26 |
Sale |
84.02 |
1,550 |
130,231 |
35,832 |
| AUGUSTINOS NICHOLAS | Director |
Sep 14 '26 |
Proposed Sale |
84.02 |
1,550 |
130,231 |
0 |
| Sylvain Jereme M | EVP, Chief Financal Officer |
Sep 10 '26 |
Sale |
83.27 |
3,638 |
302,936 |
146,828 |
3.49%
자본화:
|
볼륨(24시간):